COLLEGIUM PHARMACEUTICAL, INC: Janus Henderson Group Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Janus Henderson Group Ltd. amended its Schedule 13G stake filing for Collegium Pharmaceutical, Inc., disclosing the change to the SEC under accession number 0001274173-26-000263. The filing updates the institutional investor's reported position in the specialty pharmaceutical company, though the amended document did not specify the revised share count or percentage in the headline disclosure. The move matters because 13G amendments signal shifts in passive or institutional ownership that can influence Collegium's shareholder base and governance dynamics. Investors will watch for the detailed ownership figures in the full filing and any subsequent 13F disclosures for confirmation of Janus Henderson's current stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Collegium Pharmaceutical, Inc., Janus Henderson Group Ltd.